GLSI-100 clinical trials

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

This study is testing a new immunotherapy, GLSI-100, for people with a specific type of HER2-positive breast cancer to see if it can stop the cancer from coming back. It involves injections given over time.